Clinical trials: Hair Loss
Eyelash Hypotrichosis, Alopecia Areata
Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children
This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily application to the upper eyelid margins compared with vehicle in treating eyelash loss or hypotrichosis (inadequate or not enough…
- Trial name
- NCT01023841
- Testing
- bimatoprost ophthalmic solution 0.03%, Vehicle Sterile Solution
- Where
- 2 sites in United States, Brazil
- Volunteers
- 71 people
- Sponsor
- Allergan
Alopecia Areata
PF-06651600 for the Treatment of Alopecia Areata
This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss.
- Trial name
- ALLEGRO-2b/3 (NCT03732807)
- Testing
- PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2
- Where
- 155 sites in United States, Argentina and 16 more
- Volunteers
- 718 people
- Sponsor
- Pfizer
Alopecia Areata
A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age
The purpose of the study is to evaluate the pharmacokinetics (how the medicine is changed and eliminated from your body after you take it) and pharmacodynamics (effects of the medicine in the body) of the study medicine (called…
- Trial name
- NCT05650333
- Testing
- Ritlecitinib 20 mg
- Where
- 9 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
Alopecia, Sensitive Skin
A Scalp Lotion Toimprove Sensitive Scalp Syndrome
Overall, 100 Caucasian subjects participated in this 6-weeks lasting study, AC5+ was applied daily. All subjects had clinically confirmed mild to moderate alopecia and self-declared sensitive scalp.
- Trial name
- NCT05630027
- Testing
- Piroctone Olamine (PO), 2,4 Diaminopyrimidine oxide (2.4 DA) and Vichy mineralizing water
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Cosmetique Active International
Androgenetic Alopecia
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss
The primary purpose of the study is to evaluate the efficacy of a topical 5% minoxidil formulation in males for the treatment of pattern hair loss.
- Trial name
- NCT00151515
- Testing
- minoxidil
- Where
- 15 sites in United States
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Alopecia Areata
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata.
- Trial name
- ALLEGRO-100 (NCT06873945)
- Testing
- Ritlecitinib 100 mg, Ritlecitinib 50 mg
- Where
- 148 sites in United States, Canada and 9 more
- Volunteers
- 674 people
- Sponsor
- Pfizer
Crohn Disease, Ulcerative Colitis
Expanded Access to Upadacitinib
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis
- Trial name
- NCT04159597
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Alopecia Areata, Pediatric Disorder
Efficacy and Safety of LH-8 in Paediatric Alopecia Areata
Double-blind, randomised, multi-centre study to evaluate the efficacy and safety of LH-8 cutaneous solution versus placebo in children and adolescents with moderate to severe scalp alopecia areata.
- Trial name
- AA (NCT03240627)
- Testing
- LH-8
- Where
- 3 sites in Bulgaria, France and 1 more
- Volunteers
- 107 people
- Sponsor
- Legacy Healthcare SA
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Severe Alopecia Areata
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the scalp and face, but hair loss can happen on any hair-bearing part of the body.
- Trial name
- NCT07772492
- Testing
- Upadacitinib
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 300 people
- Sponsor
- AbbVie
Severe Alopecia Areata
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
The purpose of this study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the possible treatment of severe alopecia areata. Alopecia areata is a condition that causes hair loss.
- Trial name
- B7981027 (NCT07029711)
- Testing
- Ritlecitinib higher dose, Ritlecitinib lower dose
- Where
- 84 sites in United States, China and 7 more
- Volunteers
- 208 people
- Sponsor
- Pfizer
Alopecia Areata
Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US
Alopecia areata (AA) is a chronic, relapsing T-cell mediated autoimmune disease characterized by nonscarring, typically patchy hair loss that affects people of all ages, races, and genders.
- Trial name
- NCT07226531
- Testing
- Ritlecitinib
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Pfizer
Acne, Acne Vulgaris
Clinical Workflow Optimization Using Artificial Intelligence for Dermatological Conditions
Artificial intelligence (AI) based on imaging holds tremendous potential to enhance visual diagnostic accuracy in the medical field.
- Conditions
- Acne, Acne Vulgaris, Alopecia, Androgenetic, Pigmented Lesions
- Trial name
- IDEI_2023 (NCT06263413)
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- AI Labs Group S.L
Non-Segmental Vitiligo (NSV), Alopecia Areata
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global…
- Conditions
- Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa
- Trial name
- MEASUREAAVitHS (NCT07136467)
- Where
- 116 sites in Argentina, Canada and 16 more
- Volunteers
- 2,795 people
- Sponsor
- AbbVie
Alopecia; X-Rays
Radiation- Induced Alopecia in Patients Undergoing Radiation Therapy to the Brain
Study will be conducted on patients receiving Whole brain(WB) / Partial Brain(PB) radiotherapy using volumetric modulated arc therapy or intensity modulated radiotherapy at Department of Radiation Oncology, Fortis Memorial…
- Trial name
- NCT03543020
- Testing
- radiation therapy to brain
- Where
- India
- Volunteers
- 25 people
- Sponsor
- Fortis Memorial Research Institute
Atopic Dermatitis, Alopecia Areata
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice.
- Conditions
- Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo
- Trial name
- TARGET-DERM (NCT03661866)
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 15,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Alopecia Areata
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body.
- Trial name
- Up-AA (NCT06012240)
- Testing
- Upadacitinib
- Where
- 272 sites in United States, Argentina and 26 more
- Volunteers
- 1,500 people
- Sponsor
- AbbVie
Alopecia Areata
Healthcare Disparities in Alopecia Areata
Alopecia areata (AA) is a common immune-mediated non-scarring alopecia often associated with substantial morbidity. There are however, limited population-based data on potential disparities in the burden of AA, including across…
- Trial name
- NCT05727306
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 4,052,231 people
- Sponsor
- Momentum Data
Sensorineural Hearing Loss, Tinnitus
Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss
The HEAR-RESTORE study is an exploratory clinical research program designed to evaluate new diagnostic and regenerative approaches for individuals experiencing inner ear injury, tinnitus, and temporary or permanent hearing loss.
- Conditions
- Sensorineural Hearing Loss, Tinnitus, Acoustic Trauma, Inner Ear Injury
- Trial name
- HEAR-RESTORE (NCT07472023)
- Testing
- Audiologic Monitoring, Investigational Regenerative Pharmacologic Therapy, Stem Cell Regenerative Therapy
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Truway Health, Inc.
Alopecia Areata
Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)
Provide pre-approval single patient Expanded Access (compassionate use) of Ritlecitinib for patients.
- Trial name
- NCT05522556
- Testing
- Ritlecitinib
- Sponsor
- Pfizer